Seroquel XR Dosage

Generic name: quetiapine fumarate
Dosage form: tablet, extended release

This dosage information does not include all the information needed to use Seroquel XR safely and effectively. See full prescribing information for Seroquel XR.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Important Administration Instructions

SEROQUEL XR tablets should be swallowed whole and not split, chewed or crushed.

It is recommended that SEROQUEL XR be taken without food or with a light meal (approximately 300 calories) [see Clinical Pharmacology (12.3)].

SEROQUEL XR should be administered once daily, preferably in the evening.

Recommended Dosing

The recommended initial dose, titration, dose range and maximum SEROQUEL XR dose for each approved indication is displayed in Table 1 below. After initial dosing, adjustments can be made upwards or downwards, if necessary, depending upon the clinical response and tolerability of the patient [see Clinical Studies (14.1, 14.2 and 14.3)].

Table 1: Recommended Dosing for SEROQUEL XR

Indication

Initial Dose and Titration

Recommended Dose

Maximum Dose

Schizophrenia- Adults

Day 1: 300 mg/day

Dose increases can be made at intervals as short as 1 day and in increments of up to 300 mg/day

400-800 mg/day

800 mg/day

Schizophrenia-Adolescents (13 to 17 years)

Day 1: 50 mg/day

Day 2: 100 mg/day

Day 3: 200 mg/day

Day 4: 300 mg/day

Day 5: 400 mg/day

400-800 mg/day

800 mg/day

Schizophrenia Maintenance-Monotherapy-Adults

n/a

400-800 mg/day

800 mg/day

Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults

Day 1: 300 mg/day

Day 2: 600 mg/day

Day 3: between 400 and 800 mg/day

400-800 mg/day

800 mg/day

Bipolar I Disorder, manic -Acute monotherapy -Children and Adolescents (10 to 17 years)

Day 1: 50 mg/day

Day 2: 100 mg/day

Day 3: 200 mg/day

Day 4: 300 mg/day

Day 5: 400 mg/day

400-600 mg/day

600 mg/day

Bipolar Disorder, Depressive Episodes-Adults

Day 1: 50 mg/day

Day 2: 100 mg/day

Day 3: 200 mg/day

Day 4: 300 mg/day

300 mg/day

300 mg/day

Bipolar I Disorder Maintenance- Adjunct to lithium or divalproex-Adults

n/a

400-800 mg/day

800 mg/day

Major Depressive Disorder- Adjunctive Therapy with Antidepressants-Adults

Day 1: 50 mg/day

Day 2: 50 mg/day

Day 3: 150 mg/day

150-300 mg/day

300 mg/day

n/a-not applicable

Maintenance Treatment for Schizophrenia and Bipolar I Disorder

Maintenance Treatment—Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.1, 14.2)].

Dose Modifications in Elderly Patients

Consideration should be given to a slower rate of dose titration and a lower target dose in the elderly and in patients who are debilitated or who have a predisposition to hypotensive reactions [see Use in Specific Populations (8.5, 8.7) and Clinical Pharmacology (12)]. When indicated, dose escalation should be performed with caution in these patients.

Elderly patients should be started on SEROQUEL XR 50 mg/day and the dose can be increased in increments of 50 mg/day depending on the clinical response and tolerability of the individual patient.

Dose Modifications in Hepatically Impaired Patients

Patients with hepatic impairment should be started on SEROQUEL XR 50 mg/day. The dose can be increased daily in increments of 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient.

Dose Modifications when used with CYP3A4 Inhibitors

SEROQUEL XR dose should be reduced to one sixth of original dose when co-medicated with a potent CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). When the CYP3A4 inhibitor is discontinued, the dose of SEROQUEL XR should be increased by 6 fold [see Clinical Pharmacology (12.3) and Drug Interactions 7.1)].

Dose Modifications when used with CYP3A4 Inducers

SEROQUEL XR dose should be increased up to 5 fold of the original dose when used in combination with a chronic treatment (e.g., greater than 7-14 days) of a potent CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.). The dose should be titrated based on the clinical response and tolerance of the individual patient. When the CYP3A4 inducer is discontinued, the dose of SEROQUEL XR should be reduced to the original level within 7-14 days [see Clinical Pharmacology (12.3) and Drug Interactions (7.1)].

Reinitiation of Treatment in Patients Previously Discontinued

Although there are no data to specifically address re-initiation of treatment, it is recommended that when restarting therapy of patients who have been off SEROQUEL XR for more than one week, the initial dosing schedule should be followed. When restarting patients who have been off SEROQUEL XR for less than one week, gradual dose escalation may not be required and the maintenance dose may be reinitiated.

Switching Patients from SEROQUEL Tablets to SEROQUEL XR Tablets

Patients who are currently being treated with SEROQUEL (immediate release formulation) may be switched to SEROQUEL XR at the equivalent total daily dose taken once daily. Individual dosage adjustments may be necessary.

Switching from Antipsychotics

There are no systematically collected data to specifically address switching patients from other antipsychotics to SEROQUEL XR, or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized. When switching patients from depot antipsychotics, if medically appropriate, initiate SEROQUEL XR therapy in place of the next scheduled injection. The need for continuing existing extrapyramidal syndrome medication should be re-evaluated periodically.

More about Seroquel XR (quetiapine)

Consumer resources

Professional resources

Other formulations

Compare with other treatments for:

External resources

Hide
(web5)